Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model.
about
The resveratrol tetramer (-)-hopeaphenol inhibits type III secretion in the gram-negative pathogens Yersinia pseudotuberculosis and Pseudomonas aeruginosaSmall-Molecule Inhibitors of the Type III Secretion SystemChemical inhibitors of the type three secretion system: disarming bacterial pathogensThe route less taken: pulmonary models of enteric Gram-negative infectionIsolation of Salmonella mutants resistant to the inhibitory effect of Salicylidene acylhydrazides on flagella-mediated motilityMechanism of Action and Initial, In Vitro SAR of an Inhibitor of the Shigella flexneri Virulence Regulator VirFMulti-Functional Characteristics of the Pseudomonas aeruginosa Type III Needle-Tip Protein, PcrV; Comparison to Orthologs in other Gram-negative BacteriaPotential novel antibiotics from HTS targeting the virulence-regulating transcription factor, VirF, from Shigella flexneri.MarA, SoxS and Rob of Escherichia coli - Global regulators of multidrug resistance, virulence and stress response.Concerted actions of a thermo-labile regulator and a unique intergenic RNA thermosensor control Yersinia virulence.3-Substituted Biquinolinium Inhibitors of AraC Family Transcriptional Activator VirF from S. flexneri Obtained Through In Situ Chemical Ionization of 3,4-Disubstituted DihydroquinolinesIdentification of MrtAB, an ABC transporter specifically required for Yersinia pseudotuberculosis to colonize the mesenteric lymph nodes.Identification of a small-molecule inhibitor of bacterial AraC family activators.Disarming bacterial virulence through chemical inhibition of the DNA binding domain of an AraC-like transcriptional activator protein.YopP-expressing variant of Y. pestis activates a potent innate immune response affording cross-protection against yersiniosis and tularemia [corrected].The pathogenesis, detection, and prevention of Vibrio parahaemolyticus.Pathogenesis of Y. enterocolitica and Y. pseudotuberculosis in Human Yersiniosis.Decreased expression of type 1 fimbriae by a pst mutant of uropathogenic Escherichia coli reduces urinary tract infection.Inhibition of Pseudomonas aeruginosa ExsA DNA-Binding Activity by N-Hydroxybenzimidazoles.Yersinia pseudotuberculosis uses Ail and YadA to circumvent neutrophils by directing Yop translocation during lung infection.A small-molecule compound belonging to a class of 2,4-disubstituted 1,3,4-thiadiazine-5-ones suppresses Salmonella infection in vivo.Prophylaxis and therapy of plague.Targeting the type III secretion system to treat bacterial infections.Approaches targeting the type III secretion system to treat or prevent bacterial infections.Anti-virulence Strategies to Target Bacterial Infections.Attenuating Listeria monocytogenes Virulence by Targeting the Regulatory Protein PrfA.RcsB positively regulates the Yersinia Ysc-Yop type III secretion system by activating expression of the master transcriptional regulator LcrF.Discovery of YopE Inhibitors by Pharmacophore-Based Virtual Screening and Docking.A type III secretion system inhibitor targets YopD while revealing differential regulation of secretion in calcium-blind mutants of Yersinia pestis.The bacterial type III secretion system as a target for developing new antibioticsIdentification of the Targets of Type III Secretion System Inhibitors
P2860
Q21132404-AD39C8C6-5979-42F0-8A8C-50EA24997C9AQ26781403-E9D0CFBE-08BB-42FF-B785-8025356832A9Q27013353-7C9A067C-46F9-4BC7-8EFF-9D3981918526Q27691303-846D73C0-EB4D-4AAF-955E-51EB6D63BAA2Q28484814-5B891DD1-3353-4BC1-A9FD-A4B97EF49E31Q28547782-67288055-5832-4C97-89AF-7814114226CEQ30431366-A31E9F74-1A9C-4610-9A0E-A7AFBA6EA185Q30580404-BC9FC257-C830-41E7-9556-41834419BB16Q33652762-CFD8E846-1786-49CF-AC73-FB82A27CE781Q34167887-0089E51C-5BD4-461C-9B34-CA4A95AE35F8Q34222413-888801E8-34C1-4BF5-B975-D70B8122D5B4Q34372298-8802C973-AD63-47CD-A89F-277858A9C4D8Q34567886-FEB957A7-32FF-4A6C-8EF6-6430E023F54CQ34982570-CB0E67BB-7BA7-435D-94AB-C813EE6218EDQ35073117-E2DDC081-2A07-413F-AC84-822EBF4F3BBFQ35149904-A9299761-AE09-49B3-A050-E30860D21761Q35910491-B42D3554-A8CE-49D2-B876-56B27969BF96Q36211098-E634E544-F4C5-4047-8022-7C3AEC4F0B17Q36571859-51E456F8-42E6-4079-BF8F-F37A310DDB27Q37695112-7C0693C3-5F7A-423E-9D33-06C6FCD6E2F4Q37838071-6158D4FA-3DF6-401A-B619-CD38957A9FB6Q38131537-1210980F-7276-4C9B-A4F9-61D43A74C1FEQ38167861-65E35512-0108-4C88-882D-8CB1CA15B5D9Q38366322-B3412641-E81F-4945-825A-D6073D7C8CA1Q38760476-C2B394BA-6D77-47D7-98D7-863467D71C61Q38785164-FD8BB5BA-EC12-4094-B287-888C3932F497Q38974017-40FFF6C0-52D2-490B-8FAC-D5E5ACF0D07AQ39504677-DA83F2FD-0C36-4D65-A8D4-E610237613D2Q41391746-96A18F07-BE76-405A-81AE-099E477C5BE6Q42328253-B5188257-404F-46E4-A76C-19350C186095Q57920108-DC982B5F-1EDD-4718-AE16-5C49946F856B
P2860
Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Small molecule inhibitors of L ...... n in a murine pneumonia model.
@ast
Small molecule inhibitors of L ...... n in a murine pneumonia model.
@en
type
label
Small molecule inhibitors of L ...... n in a murine pneumonia model.
@ast
Small molecule inhibitors of L ...... n in a murine pneumonia model.
@en
prefLabel
Small molecule inhibitors of L ...... n in a murine pneumonia model.
@ast
Small molecule inhibitors of L ...... n in a murine pneumonia model.
@en
P2093
P2860
P356
P1476
Small molecule inhibitors of L ...... n in a murine pneumonia model.
@en
P2093
Atul K Verma
Cynthia Castillo
Joan Mecsas
Joan-Miquel Balada-Llasat
Lynne K Garrity-Ryan
Michael L Fisher
Michael N Alekshun
S Ken Tanaka
Stuart B Levy
P2860
P304
P356
10.1128/IAI.01305-09
P407
P577
2010-09-07T00:00:00Z